Tempus AI has taken a significant step in advancing its precision medicine strategy by agreeing to acquire Ambry Genetics in a $600 million deal. This move, comprising $375 million in cash and $225 million in stock, signals Tempus AI’s intent to expand its genetic testing capabilities and solidify its leadership in healthcare innovation. This acquisition […]
Recursion Pharmaceuticals Inc. (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) have announced a landmark merger, combining their strengths to form a formidable entity in drug discovery and development. This strategic union is set to enhance their technological capabilities and expand their clinical pipeline, paving the way for more effective and affordable medicines. Key Details of […]
Tempus, a pioneer in artificial intelligence and precision medicine, has announced an expansion of its collaboration with pharmaceutical giant AstraZeneca. This enhanced partnership focuses on utilizing Tempus Next, a care pathway intelligence platform, to facilitate the delivery of biomarker testing for patients with non-small cell lung cancer (NSCLC), addressing critical care gaps. Enhancing Precision Medicine […]
Lantern Pharma Inc. (NASDAQ: LTRN) announced a strategic collaboration with French biotech company Oregon Therapeutics to enhance the development of XCE853, a first-in-class protein disulfide isomerase (PDI) inhibitor drug candidate. The partnership, utilizing Lantern Pharma’s proprietary RADR AI platform, aims to identify biomarkers and gene signatures that will guide XCE853’s clinical application in treating various […]
Diamyd Medical has achieved a significant milestone in its pioneering Phase 3 trial, DIAGNODE-3, of Diamyd in Type 1 Diabetes, marking the successful enrollment of 100 patients without any serious adverse events or discontinuations reported. This trial, the first-ever precision medicine Phase 3 study in Type 1 Diabetes, is currently underway in the United States […]
In a landmark transaction for the biotechnology and AI industries, APx Acquisition Corp. I (NASDAQ: APXI), OmnigenicsAI Corp, and MultiplAI Health Ltd have signed a definitive Business Combination Agreement (BCA). This deal, valued at approximately $340 million, is poised to create a leading global genomics company driven by artificial intelligence (AI), enhancing precision medicine through […]
Microsoft Corp. is expanding its longstanding partnership with NVIDIA, setting a new benchmark in the integration of generative AI, cloud, and accelerated computing within the healthcare and life sciences sectors. This collaboration converges Microsoft Azure’s global scale, security, and advanced computing prowess with NVIDIA’s DGX Cloud and the comprehensive NVIDIA Clara computing platforms, software, and […]
Zephyr AI, Inc., a pioneering healthcare technology company committed to enhancing precision medicine through fast and explainable Artificial Intelligence (AI) solutions, has successfully closed a $111 million Series A funding round. This significant financial boost was supported by a group of prestigious investors including Revolution Growth, Eli Lilly & Company, Jeff Skoll, and EPIQ Capital […]
In a groundbreaking development for the healthcare industry, CureMatch and Spesana have announced a strategic partnership aimed at advancing precision medicine and transforming patient care solutions for clinicians and patients. This collaboration seeks to integrate CureMatch’s innovative Knowledge Representation and Reasoning (KRR) AI precision medicine platform with Spesana’s clinical workflow ecosystem, promising to revolutionize patient […]
Owkin, a pioneering TechBio company known for combining human and artificial intelligence to tailor treatments for individual patients, has announced a strategic collaboration with Amazon Web Services (AWS) to innovate in the fields of drug discovery, clinical trial acceleration, and the development of AI diagnostics. Leveraging AWS’s global infrastructure and its secure, extensive, and reliable […]